biotech acquisition
Behind-the-Scenes Details of 89bio’s $2.4B Deal with Roche
Roche; 89bio; pegozafermin; MASH; liver disease; contingent value rights; biotech acquisition; pharmaceuticals; deal structure; milestone payments
Pfizer’s $4.9B Metsera Deal Signals More Pharma M&A in Booming Obesity Drug Market
Pfizer; Metsera; obesity drugs; weight loss; pharma M&A; GLP-1; biotech acquisition; pharmaceutical market; late-stage clinical development
Merck Terminates Midstage Asset from $1.9B Pandion Acquisition over Lack of Clinical Benefit
Merck; Pandion Therapeutics; asset termination; clinical trial; lack of benefit; biotech acquisition